Høhloch, Karin

[["dc.bibliographiccitation.firstpage","1031"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1038"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Altmann, Bettina"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Pöschel, Viola"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2021-04-14T08:30:49Z"],["dc.date.available","2021-04-14T08:30:49Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-04345-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83385"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Kloess, Marita"],["dc.contributor.author","Duehrsen, Ulrich"],["dc.contributor.author","Eimermacher, Hartmut"],["dc.contributor.author","Haas, A."],["dc.contributor.author","Aldaoud, A."],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Binder, Claudia"],["dc.date.accessioned","2018-11-07T09:41:02Z"],["dc.date.available","2018-11-07T09:41:02Z"],["dc.date.issued","2006"],["dc.format.extent","431S"],["dc.identifier.isi","000239009403027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33635"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","42nd Annual Meeting of the American-Society-of-Clinical-Oncology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0732-183X"],["dc.title","CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","23"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","126"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Altmann, Bettina"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:47:41Z"],["dc.date.available","2018-11-07T09:47:41Z"],["dc.date.issued","2015"],["dc.identifier.isi","000368019004309"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35161"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","57th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R-CHOP"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1121"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1128"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Feller, Alfred C."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Hasenclever, Dirk"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:13:36Z"],["dc.date.available","2018-11-07T10:13:36Z"],["dc.date.issued","2016"],["dc.description.abstract","Treatment of relapse and primary progression in aggressive lymphoma remains unsatisfactory; outcome is still poor. Better treatment strategies are much needed for this patient population. The R1 study is a prospective multi-center phase I/II study evaluating a dose finding approach with a triple transplant regimen in four BEAM dose levels in patients with relapsed aggressive non-Hodgkin lymphoma. The aim of the study was to determine feasibility, toxicity, and remission rate. In a total of 39 patients (pts.) enrolled in the study, 24 pts. were evaluated in the following analysis. Twenty pts. had aggressive B cell lymphoma, and two pts. had T cell lymphoma. All evaluated patients responded to DexaBEAM with a sufficient stem cell harvest. The phase I/II study was started with BEAM dose level II. Four patients were treated at dose level II, and 20 pts. were treated at dose level III. Due to the early termination of the study, dose levels I and IV were never administered. Sixteen pts. completed therapy according to protocol, and eight pts. (33.3 %) stopped treatment early. Infections (27 %) and stomatitis (13 %) were the most frequent grade III/IV non-hematologic toxicities. Thirteen percent of patients presented with severe grade III/IV lung toxicity during modified BEAM (m-BEAM). Fourteen pts. achieved a complete response (CR), one pt. achieved no change (NC), six pts. had progressive disease (PD), and two pts. died; for one pt., outcome is not known. One-year and 3-year event-free survival (EFS) was 38 and 33 %, respectively. Overall survival (OS) after 1 and 3 years was 50 and 38 %. In conclusion, dose escalation of standard BEAM is not feasible due to toxicity."],["dc.identifier.doi","10.1007/s00277-016-2671-5"],["dc.identifier.isi","000377185400011"],["dc.identifier.pmid","27165090"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40464"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2260"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","2263"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:33:00Z"],["dc.date.available","2018-11-07T09:33:00Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1038/leu.2014.213"],["dc.identifier.isi","000344940300021"],["dc.identifier.pmid","25005242"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31867"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1476-5551"],["dc.relation.issn","0887-6924"],["dc.title","Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","7539"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","7539"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Altmann, Bettina"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2020-12-10T18:41:30Z"],["dc.date.available","2020-12-10T18:41:30Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1200/JCO.2016.34.15_suppl.7539"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77599"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]